| US 7,590,493 B2 | ||
| Methods for determining hepatotoxins | ||
| Donna Mendrick, Gaithersburg, Md. (US); Mark Porter, Gaithersburg, Md. (US); Kory Johnson, Gaithersburg, Md. (US); Brandon Higgs, Gaithersburg, Md. (US); Arthur Castle, Gaithersburg, Md. (US); and Michael Elashoff, Gaithersburg, Md. (US) | ||
| Assigned to Ocimum Biosolutions, Inc., Indianapolis, Ind. (US) | ||
| Filed on Feb. 17, 2005, as Appl. No. 11/59,535. | ||
| Application 11/059535 is a division of application No. 10/060087, filed on Jan. 31, 2002, abandoned. | ||
| Application 10/060087 is a continuation in part of application No. 09/917800, filed on Jul. 31, 2001, abandoned. | ||
| Claims priority of provisional application 60/331273, filed on Nov. 13, 2001. | ||
| Claims priority of provisional application 60/303459, filed on Jul. 09, 2001. | ||
| Claims priority of provisional application 60/298884, filed on Jun. 19, 2001. | ||
| Claims priority of provisional application 60/297457, filed on Jun. 13, 2001. | ||
| Claims priority of provisional application 60/295798, filed on Jun. 06, 2001. | ||
| Claims priority of provisional application 60/292336, filed on May 22, 2001. | ||
| Claims priority of provisional application 60/290645, filed on May 15, 2001. | ||
| Claims priority of provisional application 60/290029, filed on May 11, 2001. | ||
| Claims priority of provisional application 60/244880, filed on Nov. 02, 2000. | ||
| Claims priority of provisional application 60/222040, filed on Jul. 31, 2000. | ||
| Prior Publication US 2007/0043515 A1, Feb. 22, 2007 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. G06F 19/00 (2006.01) | ||
| U.S. Cl. 702—19 [435/6; 700/30; 702/22; 707/104.1] | 10 Claims |
| 1. A method for determining whether a test compound is a hepatotoxin, comprising:
(a) exposing liver tissue or liver cells to the test compound;
(b) preparing a normalized gene expression profile of at least ten genes for said liver tissue or liver cells, wherein the
gene expression profile contains the differential gene expression levels for said at least ten genes upon exposure to the
test compound, and wherein said at least ten genes are listed in one of Tables 3-3DD;
(c) comparing the gene expression profile to a hepatotoxicity model, the hepatotoxicity model comprising:
(i) the normalized mean expression levels of said at least ten genes in liver tissue or liver cells exposed to a known hepatotoxin,
(ii) the normalized mean expression levels of said at least ten genes in liver tissue or liver cells not exposed to a hepatotoxin,
and
(iii) information from one or more of Tables 3-3DD; and
(d) scoring the comparison to determine whether the test compound is a hepatotoxin.
|